Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Argenx BV maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the company's current legal matters are spread across different technical specialties and personnel within the patent office.
SULLIVAN, DENNIS JOHN is the busiest examiner for this portfolio, handling 1 busiest examiner pending action. Because there are 2 distinct examiners in total, the workload is split between the assigned individuals. Practitioners should note that with 2 distinct art units involved, the prosecution strategies relate to the specific requirements of each unit. The presence of 2 pending office actions defines the volume of active responses required. Navigating 2 distinct examiners involves understanding the different sets of examiner-specific behaviors within the Biotechnology & Pharmaceuticals field. The 2 pending office actions are the only active matters currently listed.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330903 | ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USE | HADDAD, MAHER M | 58d overdue |
| 19243836 | SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF | SULLIVAN, DENNIS JOHN | 28d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19243836 | SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF | SULLIVAN, DENNIS JOHN | 1642 | §103 | Non-Final OA | 28d | Pending | Jun 20, 2025 |
| 18330903 | ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USE | HADDAD, MAHER M | 1641 | §103Other | Non-Final OA | 58d overdue | Pending | Jun 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial